摘要
目的:探讨早期非小细胞肺癌(NSCLC)患者血清巨噬细胞抑制因子-1(MIC-1)、趋化素(chemerin)水平与临床病理特征及预后的关系。方法:选择72例NSCLC患者(NSCLC组)、53例肺良性疾病患者(良性组)、50例体检健康人群(对照组),分别检测血清MIC-1、chemerin水平,分析血清MIC-1、chemerin水平与NSCLC患者临床病理参数的关系。Kaplan-Meier法分析不同血清MIC-1、chemerin水平NSCLC患者生存时间的差异,COX比例风险回归分析血清MIC-1、chemerin水平与NSCLC患者预后的关系。结果:NSCLC组患者血清MIC-1、chemerin水平高于良性组和对照组(P<0.05)。血清MIC-1水平与NSCLC患者年龄、目前吸烟、肿瘤直径、TNM分期、分化程度、复发或转移、生存状态有关(P<0.05),chemerin水平与NSCLC患者目前吸烟、TNM分期、复发或转移、生存状态有关(P<0.05)。高MIC-1水平患者生存率低于低MIC-1水平患者(P<0.05),高chemerin水平患者生存率低于低chemerin水平患者(P<0.05)。COX比例风险回归分析结果显示:血清MIC-1、chemerin、TNM分期与NSCLC不良预后独立相关。结论:血清MIC-1、chemerin水平与NSCLC患者部分临床病理参数和预后相关,可作为早期NSCLC患者预后预测的潜在指标。
Objective: To investigate the relationship between serum level of macrophage inhibitory factor-1(MIC-1) and chemerin and clinicopathological features and prognosis in patients with early non-small cell lung cancer(NSCLC). Methods: 72 patients with NSCLC(NSCLC group), 53 patients with benign pulmonary diseases(benign group) and 50 healthy people(control group) were selected. Serum MIC-1 and chemerin levels were detected respectively. The relationship between serum MIC-1 and chemerin levels and clinicopathological parameters of NSCLC patients was analyzed. The survival time of NSCLC patients with different serum levels of MIC-1 and Chemerin was analyzed by Kaplan-Meier method. The relationship between serum levels of MIC-1 and chemerin and the prognosis of NSCLC patients was analyzed by COX proportional risk regression. Results: The serum MIC-1 and chemerin levels in NSCLC group were higher than those in benign group(P<0.05). Serum MIC-1 level was correlated with age, current smoking, tumor diameter, TNM stage, differentiation degree, recurrence or metastasis, survival status of NSCLC patients(P<0.05), and chemerin level was correlated with current smoking, TNM stage, recurrence or metastasis and survival status of NSCLC patients(P<0.05). The survival rate of patients with high MIC-1 level was lower than that of patients with low MIC-1 level(P<0.05), and survival rate of patients with high chemerin level was lower than that of patients with low chemerin level(P<0.05). COX proportional risk regression analysis showed that serum MIC-1, chemerin and TNM stage levels were independently associated with poor prognosis of NSCLC. Conclusion: Serum MIC-1 and chemerin levels are correlated with some clinicopathological parameters and prognosis of NSCLC patients, and they can be used as potential prognostic indicators for early NSCLC patients.
作者
吕蒙
王昂
王杰
鄢文
尤长宣
LV Meng;WANG Ang;WANG Jie;YAN Wen;YOU Chang-xuan(Department of Oncology,Huiqiao Medical Center,Nanfang Hospital of Southern Medical University,Guangzhou,Guangdong,510000,China;First Ward of Oncology,Second People's Hospital of Guangdong Province,Guangzhou,Guangdong,510000,China;Department of Radiotherapy,Second People's Hospital of Guangdong Province,Guangzhou,Guangdong,510000,China)
出处
《现代生物医学进展》
CAS
2019年第21期4103-4107,共5页
Progress in Modern Biomedicine
基金
广东省科技计划项目(2017B090901067)
关键词
非小细胞肺癌
巨噬细胞抑制因子-1
趋化素
病理特征
预后
Non-small cell lung cancer
Macrophage inhibitor-1
Chemerin
Pathological characteristics
Prognosis